ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

GYRE vs ARVN // FREE CASH FLOW YIELD

Gyre Therapeutics Inc. (NASDAQ) VS. Arvinas Inc. (NASDAQ) • 15-METRIC TALLY: GYRE 6 — ARVN 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GYRE VS. ARVN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC GYRE ARVN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 95.40% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 25.40% -32.10% +57.50 GYRE /roic <GO>
EV/EBITDA & P/E Valuation 53.3x — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE -0.03% — — TIE /fcf-yield <GO>
Operating Margin 9.90% -45.10% +55.00 GYRE /operating-margins <GO>
Net Profit Margin 8.50% -30.80% +39.30 GYRE /net-margins <GO>
Revenue Growth (YoY) 10.20% -0.30% +10.50 GYRE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 14.33 0.20 +14.13 GYRE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 3/9 +2.00 GYRE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 38.0 54.4 -16.40 ARVN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 67.2x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $507.9M $513.9M -$6.0M ARVN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR GYRE REV ARVN REV GYRE GROSS % ARVN GROSS % GYRE FCF ARVN FCF
FY 2025 $116.6M $262.6M 95.4% — -$180.0K -$275.7M
FY 2024 $105.8M $263.4M 96.3% — -$6.0M -$261.1M
FY 2023 $113.5M $78.5M — — $25.9M -$347.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GYRE // BETA —
ARVN // BETA —